AccuGenomics joins the FNIH Biomarkers Consortium focused on Measurable residual disease in acute myeloid leukemia (MRD in AML)

AccuGenomics Inc is pleased to announce that it has joined the FNIH Biomarkers Consortium focused on Measurable residual disease in acute myeloid leukemia (MRD in AML). We look forward to our participation in advancing the accuracy of targeted NGS testing of liquid biopsy samples.As a disruptive precision diagnostics technology company, AccuGenomics’s mission is to improve the accuracy and performance of…

Read more

Stay Informed

Get the latest updates and news

Linkedin

© 2020 AccuGenomics, Inc. All Rights Reserved.